Dupilumab Compassionate Use Study
NCT03020810 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2018-03-07
Summary
This is a single patient expanded access, compassionate and non-emergency use study that provides patients with severe asthma, who do not qualify for ongoing clinical trials with dupilumab, access to this investigational treatment.
Conditions
Interventions
- DRUG
-
The patient will receive a 600 mg subcutaneous dupilumab loading dose on Day 1, and then 300 mg subcutaneous dupilumab every 2 weeks
Sponsors & Collaborators
-
Sally E. Wenzel MD
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Withdrawal of Dupilumab in Severe Asthma
NCT06818019 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
A Dose-Finding Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Adalimumab in Subjects With Refractory Asthma
NCT00512863 ·Status: WITHDRAWN ·Phase: PHASE2
-
Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma
NCT01691521 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma
NCT02573233 ·Status: COMPLETED ·Phase: PHASE2
-
A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatment With Dupilumab Injection (Dupixent®)
NCT05070663 ·Status: COMPLETED
-
Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients
NCT00482508 ·Status: COMPLETED ·Phase: PHASE3
-
Dupilumab for Severe Asthma in a Real Life Setting
NCT04022447 ·Status: COMPLETED
-
A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma
NCT03562195 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Quality of Life in Male and Female Adult Participants With Severe Asthma Treated With Dupilumab in a Real-world Setting
NCT06018441 ·Status: COMPLETED
-
A Study of CM310 in Subjects With Moderate to Severe Asthma
NCT05761028 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
A Study of CM310 in Subjects With Moderate to Severe Asthma
NCT05186909 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Omalizumab in Moderate to Severe Bronchial Asthma
NCT00232050 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma
NCT05036733 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma
NCT00207740 ·Status: COMPLETED ·Phase: PHASE2
-
Investigating Dupilumab's Effect in Asthma by Genotype
NCT03694158 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients
NCT02555371 ·Status: COMPLETED ·Phase: PHASE3
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
NCT04743791 ·Status: RECRUITING ·Phase: PHASE4
-
The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma
NCT00133042 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma
NCT00485576 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma
NCT00180011 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma
NCT02528214 ·Status: COMPLETED ·Phase: PHASE3
-
An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
NCT01854047 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Dupilumab in Children With Uncontrolled Asthma
NCT02948959 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)
NCT02414854 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Mepolizumab Autoinjector in Asthmatics
NCT03099096 ·Status: COMPLETED ·Phase: PHASE3